Alkem Laboratories Quarterly Results for Trading Insights
In Sept 2025, Alkem Laboratories (ALKEM) reported revenue ₹4,105 Cr and net profit ₹779 Cr — revenue +15.7% YoY. Also explore ALKEM share price charts to track price trends across different timeframes.
ALKEM Quarterly Results — Revenue, Profit & EPS Highlights
Alkem Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with ALKEM DCF valuation to assess whether the stock is under or overvalued.
- Revenue of ₹4,105 Cr in Sept 2025 (+24.8% vs Mar 2025, +15.7% vs Sept 2024)
- Net Profit of ₹779 Cr in Sept 2025 (+141.9% vs Mar 2025, +11.0% vs Sept 2024)
- EBITDA of ₹1,025 Cr in Sept 2025 (+90.9% vs Mar 2025)
- Operating Margin of 23.0% in Sept 2025 (+11.0pp vs Mar 2025)
- Earnings Per Share of ₹63.99 in Sept 2025 (+150.3% vs Mar 2025)
Alkem Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
ALKEM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 4,105 | 3,290 | 3,521 | 3,880 | 3,549 | 24.8% | 15.7% |
| Net Profit (₹ Cr) | 779 | 322 | 668 | 653 | 702 | - | - |
| EBITDA (₹ Cr) | 1,025 | 537 | 889 | 918 | 887 | - | - |
| EPS (₹) | 63.99 | 25.57 | 55.56 | 53.19 | 57.60 | - | - |
| Operating Margin (%) | 23.0% | 12.0% | 22.0% | 21.0% | 22.0% | - | - |
ALKEM Share Price Trend — 1-Year Movement Across Quarterly Results
Alkem Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Alkem Laboratories screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
ALKEM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Alkem Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1799.2 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 159.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6667.0 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 235.5 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4410.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 383.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1401.0 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 203.9 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1303.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 491.9 |
All amounts in ₹ Crores